©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 61-66, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/1226166 IDOSRJES12206

Next-Generation Nanomedicine for Obesity and Diabetes: Mechanisms, Challenges, and Translational Opportunities: A Mini-Review

Namirimu Sandrah

Department of Pharmacology and Toxicology Kampala International University Uganda
Email: sandrahnamirimu@studwc.kiu.ac.ug

ABSTRACT

Obesity and type 2 diabetes (T2D) are major contributors to the global health crisis, characterized by insulin resistance, impaired glucose metabolism, and systemic inflammation. The progression of these metabolic disorders is driven by the dysfunction of key organs such as adipose tissue, liver, muscle, and pancreas. Traditional therapeutic approaches often fail to address the underlying molecular mechanisms, focusing more on symptom management rather than correcting the metabolic dysfunction at the root of these diseases. Next-generation nanomedicine, with its ability to deliver drugs precisely and modulate specific biological pathways, holds immense promise for treating obesity and diabetes by targeting these molecular mechanisms. This review explores the innovative mechanisms of nanomedicine in addressing the core issues of obesity and diabetes, such as inflammation, insulin resistance, and β-cell dysfunction. Additionally, we discuss the challenges of translating these technologies from the laboratory to clinical practice, including safety concerns, patient variability, and regulatory hurdles. The review also highlights the translational opportunities of next-generation nanomedicine, with an emphasis on the development of smart nanocarriers, biomolecular modulation, and targeted delivery systems aimed at improving therapeutic outcomes for obesity and T2D.

Keywords: Nanomedicine, Obesity, Type 2 Diabetes, Insulin Resistance, Translational Medicine, Drug Delivery.

INTRODUCTION

Obesity and type 2 diabetes (T2D) are leading global health challenges, with increasing prevalence rates over the past few decades. These conditions are closely interconnected, with obesity serving as the primary risk factor for the development of T2D[1–4]. The key pathological feature of both diseases is insulin resistance, where tissues become less responsive to insulin, impairing glucose uptake and leading to chronic hyperglycemia. Metabolic inflammation, driven by the dysfunction of adipose tissue, plays a central role in the development of insulin resistance and the progression of T2D[5, 6].

Traditional treatment options, including lifestyle modifications, oral hypoglycemic drugs, and insulin therapy, mainly focus on managing blood glucose levels rather than addressing the root causes of the disease[7]. This has led to a demand for more effective therapies that can target the underlying metabolic dysfunction. Nanomedicine, with its ability to precisely deliver therapeutic agents and modulate specific molecular pathways, offers a transformative approach to treating these metabolic disorders[7–9]. The ability to engineer nanoparticles that can specifically target tissues such as adipose tissue, liver, and pancreas, deliver drugs directly to the sites of action, and modulate biological processes at the molecular level, positions nanomedicine as a next-generation solution for obesity and diabetes treatment. This review explores the mechanisms by which nanomedicine can target obesity-related metabolic dysfunction, addressing insulin resistance, inflammation, and β-cell dysfunction. It also highlights the challenges of translating nanotechnology from the laboratory to the clinic and the translational opportunities that lie ahead in improving treatment outcomes for these complex metabolic diseases.

Mechanisms of Nanomedicine in Obesity and Diabetes Treatment

The therapeutic promise of nanomedicine in obesity and type 2 diabetes (T2D) is rooted in its ability to precisely target and modulate the complex molecular networks underlying insulin resistance, chronic inflammation, and pancreatic β-cell dysfunction[10–13]. Unlike conventional pharmacotherapy, which often suffers from poor bioavailability, off-target toxicity, and limited tissue specificity, nanomedicine enables enhanced drug stability, controlled release, and targeted delivery at the cellular and molecular levels. These properties make nanotechnology particularly well suited for addressing the multifactorial pathophysiology of metabolic disorders[10, 14, 15].

Targeting Insulin Resistance with Nanomedicine

Insulin resistance is a defining feature of obesity-associated diabetes, characterized by impaired insulin signaling in metabolically active tissues such as skeletal muscle, liver, and adipose tissue[16–18]. This defect disrupts glucose uptake and utilization, leading to hyperglycemia and compensatory hyperinsulinemia. Nanomedicine provides an effective platform for targeting insulin resistance by delivering insulin-sensitizing agents directly to these tissues.

Nanocarriers can encapsulate established antidiabetic drugs, including metformin, thiazolidinediones (TZDs), and glucagon-like peptide-1 (GLP-1) receptor agonists, enhancing their pharmacokinetic profiles and tissue specificity[19–22]. For example, liver-targeted nanoparticles can improve hepatic insulin sensitivity by suppressing gluconeogenesis, while muscle-targeted systems can enhance glucose uptake through improved insulin receptor signaling and GLUT4 translocation[23]. Surface modification with tissue-specific ligands further enhances selective uptake, minimizing systemic exposure and adverse effects[9, 24, 25].

Polymeric, lipid-based, and hybrid nanoparticles also allow controlled and stimuli-responsive drug release, enabling therapeutic agents to be released in response to local pH, enzymatic activity, or redox conditions. Such precision ensures that insulin-sensitizing drugs act primarily at sites of metabolic dysfunction, improving therapeutic efficacy while reducing toxicity.

Modulating Inflammation with Nanotechnology

Chronic low-grade inflammation is a central driver of insulin resistance in obesity and T2D. Expanded adipose tissue, particularly visceral fat, secretes pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), which interfere with insulin signaling pathways[26, 27]. Nanotechnology offers a targeted strategy to suppress this pathological inflammation. Nanoparticles can deliver anti-inflammatory drugs, peptides, or nucleic acid-based therapeutics directly to inflamed adipose tissue or skeletal muscle[26]. Liposomes and solid lipid nanoparticles (SLNs) are especially effective for encapsulating hydrophobic anti-inflammatory agents, enabling sustained and localized release. RNA-based approaches, including siRNA or miRNA delivery, can selectively silence inflammatory mediators or transcription factors such as NF-κB, thereby reducing cytokine production and restoring insulin responsiveness[26].

Targeted modulation of inflammation using nanomedicine not only improves insulin sensitivity but also mitigates tissue damage and metabolic deterioration, highlighting its dual therapeutic benefit.

Restoring β-Cell Function and Insulin Secretion

Progressive β-cell dysfunction is a hallmark of T2D progression. Chronic metabolic stress, glucotoxicity, and lipotoxicity impair β-cell survival and insulin secretory capacity[28, 29]. Nanomedicine offers innovative strategies to preserve and restore β-cell function by delivering protective and regenerative agents directly to pancreatic islets.

Nanoparticle-based delivery of GLP-1 agonists enhances glucose-dependent insulin secretion, promotes β-cell survival, and reduces apoptosis[30]. Encapsulation protects these peptides from enzymatic degradation and allows sustained release, improving glycemic control. Additionally, nanoparticles can deliver antioxidants, growth factors, or RNA therapeutics to counter oxidative stress and enhance β-cell resilience[30].

More advanced approaches involve the nanoparticle-mediated delivery of gene-editing tools such as CRISPR-Cas9, enabling targeted correction of genes involved in β-cell identity, insulin biosynthesis, and stress resistance[31]. Collectively, these mechanisms position nanomedicine as a powerful tool for addressing both the causes and consequences of β-cell failure in T2D.

Challenges in Translating Nanomedicine for Obesity and Diabetes

Despite its transformative potential, the clinical translation of nanomedicine for obesity and diabetes faces significant scientific, regulatory, and logistical challenges. Addressing these barriers is essential for the successful integration of nanotherapeutics into routine clinical practice.

Safety and Biocompatibility: Safety remains one of the most critical concerns in nanomedicine development. Due to their small size and high surface reactivity, nanoparticles can interact unpredictably with biological systems[32–34]. Following systemic administration, nanoparticles may accumulate in organs such as the liver, spleen, kidneys, and lungs, raising concerns about long-term toxicity, immune activation, and chronic inflammation. For metabolic diseases that require prolonged treatment, it is essential to evaluate nanoparticle biodegradability, clearance mechanisms, and cumulative toxicity. Rigorous preclinical studies, including long-

term exposure and dose-escalation assessments, are needed to establish safety profiles[33]. The use of biodegradable and bioinspired nanomaterials may help mitigate these risks.

Patient Variability and Personalized Medicine: Obesity and T2D are highly heterogeneous disorders influenced by genetic, environmental, and lifestyle factors[3, 26, 35, 36]. This variability complicates treatment outcomes and limits the effectiveness of uniform therapeutic approaches. Nanomedicine must therefore evolve toward personalized strategies that account for individual disease phenotypes and metabolic profiles. Tailoring nanoparticle composition, targeting ligands, and drug payloads based on patient-specific biomarkers or genetic information could significantly enhance therapeutic efficacy. However, implementing personalized nanomedicine requires advances in diagnostic tools, biomarker identification, and scalable manufacturing techniques.

Regulatory and Manufacturing Challenges: The regulatory approval process for nanomedicines remains under development. Regulatory agencies such as the U.S. Food and Drug Administration are still refining frameworks to assess nanoparticle safety, efficacy, and quality[32, 37–39]. Nanotherapeutics must meet stringent requirements for physicochemical characterization, pharmacokinetics, and reproducibility, often exceeding those for conventional drugs. Manufacturing scalability and batch-to-batch consistency also pose major challenges. Many nanoparticle formulations are difficult to produce at scale while maintaining uniform size, stability, and drug-loading efficiency[40]. Developing cost-effective, GMP-compliant manufacturing processes is essential for clinical translation and widespread adoption.

Translational Opportunities for Nanomedicine in Obesity and Diabetes

Despite these challenges, nanomedicine presents significant translational opportunities that could redefine the management of obesity and T2D. Advances in nanomaterial engineering, systems biology, and precision medicine are driving the development of next-generation nanotherapeutics with enhanced efficacy and safety.

Smart Nanocarriers: Smart nanocarriers capable of responding to physiological cues such as pH, glucose levels, oxidative stress, or enzymatic activity represent a breakthrough in targeted therapy[41, 42]. These systems can release therapeutic payloads only under disease-specific conditions, reducing systemic exposure and adverse effects.

In obesity and diabetes, smart nanocarriers can be engineered to respond to inflammatory signals or hyperglycemic states, ensuring on-demand drug release. Furthermore, multifunctional smart nanoparticles can co-deliver multiple agents, simultaneously targeting insulin resistance, inflammation, and β-cell dysfunction.

Combination Therapies: Nanomedicine enables the rational design of combination therapies within a single delivery platform. For example, nanoparticles can concurrently deliver insulin sensitizers, anti-inflammatory agents, and β-cell–protective compounds, addressing multiple disease mechanisms in parallel[43–45]. This integrated approach is particularly advantageous for complex metabolic disorders, where single-target therapies often fail to achieve durable efficacy.

By improving drug synergy, reducing dosing frequency, and minimizing side effects, combination nanotherapies have the potential to significantly enhance treatment outcomes and patient adherence.

CONCLUSION

Next-generation nanomedicine offers a promising solution to the challenges of treating obesity and type 2 diabetes. By targeting key molecular pathways involved in insulin resistance, inflammation, and β-cell dysfunction, nanomedicine can provide more precise and effective treatments than conventional therapies. However, challenges related to safety, patient variability, and regulatory approval must be addressed before these therapies can be widely implemented in clinical practice. With continued advancements in nanotechnology, personalized approaches, and smart nanocarriers, the future of nanomedicine in obesity and diabetes treatment is bright, with the potential to significantly improve patient outcomes and reduce the global burden of metabolic diseases.

REFERENCES

1. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G.D., Monda, M., Marra, M.L.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, (2025). https://doi.org/10.3390/healthcare13121437
2. Oh, K.-J., Lee, D.S., Kim, W.K., Han, B.S., Lee, S.C., Bae, K.-H.: Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int. J. Mol. Sci. 18, (2016). https://doi.org/10.3390/ijms18010008
3. Pillon, N.J., Loos, R.J.F., Marshall, S.M., Zierath, J.R.: Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell. 184, 1530–1544 (2021). https://doi.org/10.1016/j.cell.2021.02.012
4. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
5. Durrani, I.A., Bhatti, A., John, P.: The prognostic outcome of 'type 2 diabetes mellitus and breast cancer' association pivots on hypoxia-hyperglycemia axis. Cancer Cell Int. 21, 351 (2021). https://doi.org/10.1186/s12935-021-02040-5

6. Ryu, T.Y., Park, J., Scherer, P.E.: Hyperglycemia as a Risk Factor for Cancer Progression. Diabetes Metab. J. 38, 330–336 (2014). https://doi.org/10.4093/dmj.2014.38.5.330
7. Feingold, K.R.: Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. In: Feingold, K.R., Adler, R.A., Ahmed, S.F., Anawalt, B., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hamilton, E., Hofland, J., Jan de Beur, S., Kalra, S., Kaltsas, G., Kapoor, N., Kim, M., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrère, B., Levy, M., McGee, E.A., McLachlan, R., Muzumdar, R., Purnell, J., Rey, R., Sahay, R., Shah, A.S., Sperling, M.A., Stratakis, C.A., Trence, D.L., and Wilson, D.P. (eds.) Endotext. MDText.com, Inc., South Dartmouth (MA) (2000)
8. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
9. Omang, W.A., awa, I., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
10. Agrahari, V., and Hiremath, P.: Challenges Associated and Approaches for Successful Translation of Nanomedicines Into Commercial Products. Nanomed. 12, 819–823 (2017). https://doi.org/10.2217/nnm-2017-0039
11. Andreadi, A., Lodeserto, P., Todaro, F., Meloni, M., Romano, M., Minasi, A., Bellia, A., Lauro, D.: Nanomedicine in the Treatment of Diabetes. Int. J. Mol. Sci. 25, (2024). https://doi.org/10.3390/ijms25137028
12. Chai, B., Li, Y., Wang, Y., Yang, D., Zhang, L.: Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives. Int. J. Nanomedicine. 20, 12831–12857 (2025). https://doi.org/10.2147/IJN.S539908
13. Chen, L., Deng, X., Shen, Q., Chen, M., Li, C., Wang, S.: Novel Dual Strategy Based on EPR/AT for Optimizing Therapeutic Effect by Improving Drug Delivery System Physicochemical Properties and Regulating TME. Int. J. Nanomedicine. 21, 1–26 (2026). https://doi.org/10.2147/IJN.S559763
14. Boone, C.E., Wang, L., Gautam, A., Newton, I.G., Steinmetz, N.F.: Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 14, e1739 (2022). https://doi.org/10.1002/wnan.1739
15. Chen, Z.-Y., Liu, H.-Z., Shang, Z.-J., Luo, G.-F., Zhang, X.-Z.: Nanomedicine for targeting cancer-associated fibroblasts in cancer therapy. Theranostics. 16, 1545–1576 (2026). https://doi.org/10.7150/thno.120283
16. Wondmkun, Y.T.: Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab. Syndr. Obes. Targets Ther. 13, 3611–3616 (2020). https://doi.org/10.2147/DMSO.S275898
17. Ahmed, B., Sultana, R., Greene, M.W.: Adipose tissue and insulin resistance in obese. Biomed. Pharmacother. 137, 111315 (2021). https://doi.org/10.1016/j.biopha.2021.111315
18. Orji, U.O., Ibiam ,Udu Ama, Awoke ,Joshua Nonso, Atoki ,Ayomide Victor, Eze ,Ejike Daniel, Obasi ,Otuomasiri Divine, Ogbu ,Celestine, Ezeani ,Nkiru Nwamaka, Aloke ,Chinyere, and Aja, P.M.: Ethanolic extract of Cnidoscolus aconitifolius leaves alleviates insulin resistance by modulating oxidative stress and inflammation in albino rats exposed to heavy metal mixture. Nat. Prod. Res. 0, 1–14. https://doi.org/10.1080/14786419.2025.2478654
19. Alshammari, E.M.: Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications. Discov. Nano. 20, 226 (2025). https://doi.org/10.1186/s11671-025-04379-4
20. Bera, R., Pathak, S., Srivastava, P., Ghosh, M., Sharma, A., Ahmed, N.Z., Karwasra, R., Akram, U., Kumar, P., Sharma, B., Sharma, N.: Biomimetic nanocarriers for the therapy and management of intestinal inflammations. Int. J. Pharm. X. 10, 100377 (2025). https://doi.org/10.1016/j.ijpx.2025.100377
21. Daoud, E., Abdulsahib, W.K., Ismael, S.H., Roopashree, R., Ray, S., Nellore, J., Mukherjee, G., Chauhan, A.S., Kholiyeva, M.: Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier. Discov. Oncol. 16, 2286 (2025). https://doi.org/10.1007/s12672-025-04057-y
22. Irie, T., Das, S., Negishi, Y.: Covalent organic frameworks as precision nanocarriers for targeted drug delivery: developments, hurdles, and horizons. Nanoscale Horiz. (2026). https://doi.org/10.1039/D5NH00612K
23. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
24. Shetab Boushehri, M.A.: Long circulating nanocarriers: achievements and shortcomings of biomimetic approaches. Int. J. Pharm. 689, 126488 (2026). https://doi.org/10.1016/j.ijpharm.2025.126488

25. Zeinali, R., Zaeifi, D., Zolfaghari-Moghaddam, S.Y., Paul, M.K., Biazar, E.: Current Advances in Nanocarriers for Cancer Therapy. Int. J. Nanomedicine. 20, 12217–12262 (2025). https://doi.org/10.2147/IJN.S548088
26. Rohm, T.V., Meier, D.T., Olefsky, J.M., Donath, M.Y.: Inflammation in Obesity, Diabetes and related Disorders. Immunity. 55, 31–55 (2022). https://doi.org/10.1016/j.immuni.2021.12.013
27. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
28. Lv, C., Sun, Y., Zhang, Z.Y., Aboelela, Z., Qiu, X., Meng, Z.-X.: β-cell dynamics in type 2 diabetes and in dietary and exercise interventions. J. Mol. Cell Biol. 14, mjac046 (2022). https://doi.org/10.1093/jmcb/mjac046
29. Miao, L., Miao, R., Yao, Y., Fang, X., Guan, H., Tian, J., Tong, X.: Metabolic reprogramming of pancreatic beta cells in type 2 diabetes and its therapeutic strategy. Ageing Res. Rev. 113, 102938 (2026). https://doi.org/10.1016/j.arr.2025.102938
30. Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Feng, C., Mi, J., Pan, H., Wu, J., Huang, B., Wu, A.: Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. J. Nanobiotechnology. 23, 682 (2025). https://doi.org/10.1186/s12951-025-03677-4
31. Lotfi, M., Morshedi Rad, D., Mashhadi, S.S., Ashouri, A., Mojarrad, M., Mozaffari-Jovin, S., Farrokhi, S., Hashemi, M., Lotfi, M., Ebrahimi Warkiani, M., Abbaszadegan, M.R.: Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells. Stem Cell Rev. Rep. 19, 2576–2596 (2023). https://doi.org/10.1007/s12015-023-10585-3
32. De Jong, W.H., Geertsma, R.E., Borchard, G.: Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Deliv. Transl. Res. 12, 2042–2047 (2022). https://doi.org/10.1007/s13346-022-01208-4
33. Janjua, T.I., Cao, Y., Kleitz, F., Linden, M., Yu, C., Popat, A.: Silica nanoparticles: A review of their safety and current strategies to overcome biological barriers. Adv. Drug Deliv. Rev. 203, 115115 (2023). https://doi.org/10.1016/j.addr.2023.115115
34. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
35. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961
36. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
37. Basurto-Olvera, P., Serrano, H., Maldonado-Bernal, C.: Regulatory T cells in cancer: from immunosuppression to therapeutic targeting. Front. Immunol. 16, 1703211. https://doi.org/10.3389/fimmu.2025.1703211
38. Khan, S., Huda, B., Bhurka, F., Patnaik, R., Banerjee, Y.: Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms26178429
39. Mennella, C., Maniscalco, U., De Pietro, G., Esposito, M.: Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 10, e26297 (2024). https://doi.org/10.1016/j.heliyon.2024.e26297
40. Li, G., Fang, X., Liu, Y., Lu, X., Liu, Y., Li, Y., Zhao, Z., Liu, B., Yang, R.: Lipid Regulatory Element Interact with CD44 on Mitochondrial Bioenergetics in Bovine Adipocyte Differentiation and Lipometabolism. J. Agric. Food Chem. 72, 17481–17498 (2024). https://doi.org/10.1021/acs.jafc.4c02434
41. Emadi, R., Amiri, Z., Moghadam, F.M., Raoufi, S., Moradi, M.Z., Asadi, S., Cho, W.C., Hee Park, J., Voosough, A., Farani, M.R., Hwang, S.-K., Suk Huh, Y.: Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics. (2026). https://doi.org/10.1039/D5RA07117H
42. Nunziata, G., Pollonio, D., Lacroce, E., Rossi, F.: Smart pH-Responsive polymers in biomedical Applications: Nanoparticles, hydrogels, and emerging hybrid platforms. Mater. Today Chem. 49, 103063 (2025). https://doi.org/10.1016/j.mtchem.2025.103063
43. Adekiya, T.A., Hudson, T., Bakare, O., Ameyaw, E.E., Adebayo, A., Olajubutu, O., Adesina, S.K.: PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed. Pharmacother. 177, 117125 (2024). https://doi.org/10.1016/j.biopha.2024.117125

44. Singh, H., Balusamy, S.R., Sukweenadhi, J., Shrivastav, A., Mohanprasanth, A., Saravanan, M., Mijakovic, I., Singh, P.: Engineering combination nanomedicines to overcome cancer resistance. RSC Adv. 16, 5128–5167. https://doi.org/10.1039/d5ra08728g
45. Zhang, M., Liu, E., Cui, Y., Huang, Y.: Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 14, 212–227 (2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0054

CITE AS: Ahabwe Edwina (2026). Next-Generation Nanomedicine for Obesity and Diabetes: Mechanisms, Challenges, and Translational Opportunities: A Mini-Review. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 61-66.
https://doi.org/10.59298/IDOSR/JES/06/1226166